Physician profile
Ruth E Anthonio
NPI 1528489762
$4,047.10
in general payments reported to CMS, 2019-2025
18 companies · $646 in 2025
The $646 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $890 · 2022: $863 · 2023: $1,235 · 2024: $413 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,642.24 | 2021-2025 | Biktarvy, Sunlenca |
| Viiv Healthcare Company | $348.85 | 2021-2023 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $334.46 | 2021-2023 | Delstrigo, Pifeltro, Dificid |
| Abbvie INC. | $226.79 | 2021-2023 | |
| Janssen Products, Lp | $99.99 | 2021 | |
| Lilly USA, LLC | $62.65 | 2022-2023 | Mounjaro |
| Novo Nordisk INC | $59.57 | 2023 | Wegovy |
| Neurocrine Biosciences, INC. | $55.87 | 2022-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.88 | 2023 | Caplyta |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Glaxosmithkline, LLC. | $28.40 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.62 | 2021 | |
| Uswm, LLC | $17.80 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.63 | 2024 | Rexulti |
| Qiagen, LLC | $17.54 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $13.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.25 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Anthonio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.